IDENTIFICATION AND USE OF COMPOUNDS FOR TREATING PERSISTENT PAIN

• US 20110150769A1
• Filed: 08/05/2010
• Published: 06/23/2011
• Est. Priority Date: 08/06/2009
• Status: Abandoned Application

• Current Assignee: California Institute of Technology, Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: Guan, Yun, Dong, Xinzhong, Liu, Qin, Anderson, David J.
• Application Number:
  US12/851,436
• Publication Number:
  US 20110150769A1
• Time in Patent Office: Days
• US Class Current: 424/9.2
• CPC Class Codes: A61K 31/5517 condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/33 derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: G01N 2333/726 G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 2800/2842 Pain, e.g. neuropathic pain, psychogenic pain
• CPC Class Codes: G01N 33/566 using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Abstract

The present application provides methods and compositions that can be used to treat persistent pain and to identify compounds that can be used for treating persistent pain. More specifically, agonists of members of the Mrgpr receptor family, particularly agonists of MrgprX1, can identified and screened for use in treating persistent pain, such as pain caused by inflammation or nerve injury.

Claims

1. A method of identifying compounds that reduce persistent pain in a mammal, comprising:

providing one or more MrgprX1 agonists;

testing the MrgprX1 agonists for their ability to reduce persistent pain;

testing the MrgprX1 agonists for their ability to modulate acute pain; and

identifying the MrgprX1 agonists that have the ability to reduce persistent pain but do not significantly modulate acute pain.

2. The method of claim 1, wherein testing for the ability to reduce persistent pain is carried out in an animal model of persistent pain.

3. The method of claim 2, wherein the animal model is a chronic constriction injury model of neuropathic pain.

4. The method of claim 1, wherein testing for the ability to modulate acute pain is carried out in an animal model of acute pain.

5. The method of claim 1, wherein said MrgprX1 agonists are small molecules, peptides, or nucleic acids.

6. The method of claim 1, wherein testing the MrgprX1 agonists for their ability to reduce persistent pain comprises administering the MrgprX1 agonists directly into spinal cord of an animal.

7. A method of treating persistent pain in a subject, comprising:

identifying a subject suffering from persistent pain; and

administering to the subject an effective amount of an MrgprX1 agonist.

8. The method of claim 7, additionally comprising the step of identifying an MrgprX1 agonist that reduces persistent pain but does not significantly change the perception of acute pain.

9. The method of claim 8, wherein the ability of the agonist to reduce persistent pain is measured in an animal model of persistent pain.

10. The method of claim 8, wherein the ability of the agonist to change the perception of acute pain is measured in an animal model of acute pain.

11. The method of claim 7, wherein said persistent pain is caused by inflammation.

12. The method of claim 7, wherein said persistent pain is caused by nerve injury.

13. The method of claim 7, wherein said MrgprX1 agonist binds to MrgprX1.

14. The method of claim 13, wherein said MrgprX1 agonist is a positive allosteric modulator of a ligand of MrgprX1.

15. The method of claim 14, wherein said ligand of MrgprX1 is selected from the group consisting of Bovine adrenal medulla 22 (BAM 22), BAM8-22, and P60 peptide.

16. The method of claim 7, additionally comprising administering a second MrgprX1 agonist.

17. The method of claim 16, wherein said MrgprX1 agonist activates MrgprX1 by enhancing the activity of the second MrgprX1 agonist.

18. The method of claim 7, where said MrgprX1 agonist is a small molecule, a peptide or a nucleic acid.

19. The method of claim 18, wherein said MrgprX1 agonist is a small molecule.

20. The method of claim 19, wherein said small molecule is selected from the group consisting of N-[3-(5-Chloro-6-oxo-4-piperazin-1-yl-6H-pyridazin-1-ylmethyl)-2-methyl-phenyl]-4-(6-methoxy-pyridin-3-yl)-benzamide, N-[3-(6-oxo-4-Piperazin-1-yl-6H-pyridazin-1-ylmethyl)-2-methylphenyl]-4-(6-methoxy-pyridin-3-yl)-benzamide, and

21. The method of claim 18, wherein said MrgprX1 agonist is a peptide.

22. The method of claim 21, wherein said peptide is selected from the group consisting of BAM 22, BAM 8-22, and P60 peptide.

23. The method of claim 7, wherein the subject is human.

24. The method claim 7, wherein said MrgprX1 agonist is delivered directed into the spinal cord of the subject.